Is a Left Ventricular Ejection Fraction (LVEF) of 16% indicative of severely impaired left ventricular function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, an LVEF of 16% is significantly low and indicates heart failure with reduced ejection fraction (HFrEF), requiring immediate medical attention and comprehensive treatment. According to the most recent guidelines, an LVEF of 16% falls into the category of severely reduced heart function, with normal LVEF ranging from 55-70% and severe reduction being below 30% 1.

Classification of Heart Failure

The 2022 AHA/ACC/HFSA guideline for the management of heart failure classifies heart failure based on left ventricular ejection fraction (LVEF) into three categories: heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with mildly reduced ejection fraction (HFmrEF) 1.

Management of HFrEF

Typical management of HFrEF includes medications such as:

  • ACE inhibitors (like enalapril 2.5-20mg twice daily) or ARBs
  • Beta-blockers (such as carvedilol 3.125-25mg twice daily)
  • Mineralocorticoid receptor antagonists (spironolactone 25-50mg daily)
  • Possibly SGLT2 inhibitors (dapagliflozin 10mg daily) Diuretics like furosemide are often needed to manage fluid overload. Patients with this severely reduced LVEF may also be candidates for device therapy such as an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) 1.

Prognosis and Risk Factors

Reduced LVEF has been consistently demonstrated to be the strongest independent predictor of sudden cardiac death (SCD) 1. The low ejection fraction means the heart is only pumping out 16% of its blood volume with each contraction, significantly compromising cardiac output and potentially leading to symptoms like shortness of breath, fatigue, and fluid retention. When LVEF is severely depressed (<15–20%), the prevailing mode of cardiac death is non-sudden, or when sudden it is often related to bradyarrhythmias or electromechanical dissociation rather than ventricular tachyarrhythmias 1.

Key Considerations

  • The trajectory of LVEF over time and the cause is important to evaluate
  • Elevated natriuretic peptide levels are supportive of the diagnosis, but normal levels do not exclude a diagnosis of HFmrEF or HFpEF
  • The clinical diagnosis of HF in these EF categories should be further supported by objective measures
  • A significant reduction in LVEF over time is a poor prognostic factor 1.

From the Research

Left Ventricular Ejection Fraction (LVEF) of 16%

  • An LVEF of 16% is considered low, indicating severe left ventricular dysfunction 2, 3.
  • Studies have shown that patients with severe left ventricular dysfunction (LVEF < 30%) may benefit from revascularization procedures such as coronary artery bypass grafting (CABG) or percutaneous revascularization 2.
  • The optimal approach to revascularization in patients with severe LV dysfunction is still a topic of debate, with some studies suggesting that CABG may be more effective in improving LV function and reducing cardiac events 2.

Treatment Options for Low LVEF

  • Beta-blockers and inhibitors of the renin-angiotensin-aldosterone system (RAAS) are commonly used to treat heart failure with reduced ejection fraction (HFrEF) 4, 5, 6.
  • These medications have been shown to improve survival and reduce morbidity in patients with HFrEF, but their effectiveness in patients with preserved ejection fraction (HFpEF) is less clear 5.
  • A study found that achieving guideline-recommended target doses of both beta-blockers and RAAS inhibitors was associated with improved outcomes in patients with HFrEF 4.

Prognosis and Outcomes

  • Patients with low LVEF (< 50%) have been shown to have worse outcomes, including increased mortality and hospitalization rates, compared to those with higher LVEF 3.
  • A decline in LVEF can begin before aortic stenosis becomes severe, and LVEF < 60% in the presence of moderate aortic stenosis predicts further deterioration of LVEF 3.
  • Treatment with beta-blockers, RAAS inhibitors, and other medications may help improve outcomes in patients with low LVEF, but more research is needed to determine the most effective treatment strategies 4, 5, 6.

Related Questions

What are the follow-up recommendations for a patient with a left ventricular ejection fraction (EF) of 20% and admitted to the hospital for chest pain?
What is the treatment for Congestive Heart Failure (CHF) in patients with a Left Ventricular Ejection Fraction (LVEF) of severely impaired systolic function?
What is the management for heart failure with reduced ejection fraction and elevated BNP levels?
What intervention improves survival in a 69-year-old female with a history of chronic hypertension, previous myocardial infarction (MI), left ventricular ejection fraction (LVEF) of 32%, and symptoms of heart failure, currently treated with aspirin (acetylsalicylic acid), atorvastatin, Lasix (furosemide), Lisinopril (Lisipril), and Toprol XL (metoprolol succinate)?
Are there any driving limitations for a patient with a history of myocardial infarction (MI), low normal left ventricular ejection fraction (LVEF), and mild to moderate aortic stenosis (AS), who is asymptomatic?
What are the differences between normal pressure hydrocephalus (NPH) and obstructive hydrocephalus?
What is the best treatment for seborrheic dermatitis of the scalp?
What is the diagnosis and treatment for Idiopathic Intracranial Hypertension (IIH), also known as Pseudotumor Cerebri?
What is the best treatment for a foot puncture wound caused by a skin thorn (foreign body)
What are the treatment options for a newborn with nasolacrimal duct obstruction?
What is the current clinical status of a 58-year-old female with a history of chronic respiratory failure, obesity hypoventilation syndrome, Chronic Obstructive Pulmonary Disease (COPD), hypertension, congestive heart failure (CHF), and morbid obesity, who is undergoing treatment for invasive ductal carcinoma of the right breast and has recently been restarted on metoprolol and Hydrochlorothiazide (HCTZ) while discontinuing amlodipine, despite continued smoking?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.